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Abstract Adenosine is known to exert most of its
physiological functions by acting as local modulator at
four receptor subtypes named A1,A 2A,A 2B and A3 (ARs).
Principally as a result of the difficulty in identifying potent
and selective agonists, the A2B AR is the least extensively
characterised of the adenosine receptors family. Despite
these limitations, growing understanding of the physiolog-
ical meaning of this target indicates promising therapeutic
perspectives for specific ligands. As A2B AR signalling
seems to be associated with pre/postconditioning cardio-
protective and anti-inflammatory mechanisms, selective
agonists may represent a new therapeutic group for patients
suffering from coronary artery disease. Herein we present
an overview of the recent advancements in identifying
potent and selective A2B AR agonists reported in scientific
and patent literature. These compounds can be classified
into adenosine-like and nonadenosine ligands. Nucleoside-
based agonists are the result of modifying adenosine by
substitution at the N
6-, C
2-positions of the purine heterocy-
cle and/or at the 5′-position of the ribose moiety or
combinations of these substitutions. Compounds 1-deoxy-
1-{6-[N′-(furan-2-carbonyl)-hydrazino]-9H-purin-9-yl}-N-
ethyl-β-D-ribofuranuronamide (19,h A 1 Ki=1050 nM,
hA2A Ki=1550 nM, hA2B EC50=82 nM, hA3 Ki>5 μM)
and its 2-chloro analogue 23 (hA1 Ki=3500 nM, hA2A Ki=
4950 nM, hA2B EC50=210 nM, hA3 Ki>5 μM) were
confirmed to be potent and selective full agonists in a cyclic
adenosine monophosphate (cAMP) functional assay in
Chinese hamster ovary (CHO) cells expressing hA2B AR.
Nonribose ligands are represented by conveniently substi-
tuted dicarbonitrilepyridines, among which 2-[6-amino-3,
5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-
ylsulfanyl]acetamide (BAY-60–6583,h A 1,h A 2A,h A 3 EC50
>10 μM; hA2B EC50=3 nM) is currently under preclinical-
phase investigation for treating coronary artery disorders
and atherosclerosis.
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Abbreviations
ABOPX 3-(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-
1-propyl-xanthine
ADP Adenosine Diphosphate
Ars Adenosine Receptors
ASMCs Arterial Smooth Muscle Cells
ATP Adenosine Triphosphate
BAY
60–6583
2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl)
pyridin-2-ylsulfanyl]acetamide
cAMP cyclic Adenosine Monophosphate
[
3H]CCPA [
3H]-2-chloro-N
6-cyclopentyladenosine
CFTR Cystic Fibrosis Transmembrane
Conductance Regulator
CGS21680 2-([4-(2-carboxyethyl)phenylethyl]amino)-
5′-N-ethylcarboxamidoadenosine
CHO cells Chinese Hamster Ovary cells
CNS Central Nervous System
COPD Chronic Obstructive Pulmonary Disease
DPCPX 1,3-dipropyl-8-cyclopentyl-xanthine
FAD Flavin Adenine Dinucleotide
GMCs Glomerular Mesangial Cells
[
3H]-CHA [
3H]N
6-cyclohexyladenosine
Purinergic Signalling (2008) 4:287–303
DOI 10.1007/s11302-008-9097-z
P. G. Baraldi (*):M. A. Tabrizi: F. Fruttarolo:R. Romagnoli:
D. Preti
Dipartimento di Scienze Farmaceutiche, Università di Ferrara,
Via fossato di Mortara 17-19,
44100 Ferrara, Italy
e-mail: baraldi@dns.unife.itHEK293
cells
Human Embryonic Kidney cells
[
125I]-AB-
MECA
[
125I]N
6-(4-amino-3-iodobenzyl)adenosine-
5′-N-methyl-uronamide
[
125I]
APNEA
[
125I]N
6–2-(4-amino-phenyl)ethyladenosine
IB-MECA N
6-(3-iodo-benzyl) adenosine-5′-N-
methyluronamide
IL Interleukin
IPC Ischemic Preconditioning
MAPK Mitogen-Activated Protein Kinase
MRE
2029-F20
N-benzo[1,3]dioxol-5-yl-2-[5-(1,3-
dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-
purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-
acetamide
MRS 1754 [N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-
2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-
phenoxy]acetamide
NAD Nicotinamide Adenine Dinucleotide
NECA 5′-N-ethylcarboxamidoadenosine
NO Nitric Oxide
OSIP339391 N-(2-(2-Phenyl-6-[4-(2,2,3,3-tetratritrio-
3-phenylpropyl)-piperazine-1-carbonyl]-
7Hpyrrolo[2,3-d]pyrimidin-4-ylamino)-
ethyl)-acetamide
PHPAdo 2-phenylhydroxypropynyladenosine
PHPNECA 2-phenylhydroxypropynyl-5′-N-
ethylcarboxamidoadenosine
R-PIA N
6-(R)-phenylisopropyladenosine
SAM S-Adenosyl-L-Methionine
TNFα Tumor Necrosis Factor α
ZM 241385 (4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-
[2,3-a][1,3,5]triazin-5-ylamino]
ethyl)-phenol
Introduction
Adenosine is involved in important biochemical processes,
such as energy transfer [adenosine triphosphate (ATP) and
adenosine diphosphate (ADP)] and signal transduction
[cyclic adenosine monophosphate (cAMP)] and it is a
building block for some biologically significant molecules
such as nicotinamide-adenine-dinucleotide (NAD), flavin-
adenine-dinucleotide (FAD), S-adenosyl-L-methionine
(SAM), DNA and RNA. The endogenous purine nucleoside
(Ado, 1, Fig. 1) is ubiquitous in mammalian cell types and,
in view of its function in regulating a wide number of
physiopathological events (such as cytoprotective, anti-
inflammatory, central nervous system neurotransmitters
regulator, pain transmission and metabolism modulator
agent [1–9]), there is wide-spread interest throughout the
scientific community in the understanding of its molecular
pharmacology and physiology.
Adenosine and ATP have been shown to induce
signalling via P1 and P2 receptors, respectively. P1
[adenosine receptors (ARs)] receptors are divided into four
subtypes, all belonging to the family of cell-membrane G-
protein-coupled adenosine receptors named A1,A 2A,A 2B
and A3, which have been cloned from many mammalian
and some nonmammalian species [10–13].
A2B ARs have been generally defined as the “low-
affinity ARs,” as their lower affinity for the endogenous
ligand, adenosine, and for some typical agonists, such as
5′-N-ethylcarboxamidoadenosine (NECA, 2,F i g .1),
N
6-(R)-phenylisopropyladenosine (R-PIA), and 2-([4-(2-
carboxyethyl)phenylethyl]amino)-5′-N-ethylcarboxamidoa-
denosine (CGS21680), by contrast with other AR subtypes
[14–15]. Under physiological conditions, intracellular
adenosine reaches a concentration of 100 nM and thus is
able to interact only with the high-affinity A1 and A2A AR
subtypes. In hypoxic, ischaemic or inflammatory condi-
tions, the intracellular levels of adenosine can grow to very
high micromolar concentrations and, thanks to specific
transports across cell membranes, the endogenous nucleo-
side can activate the low-affinity A2B and A3 AR subtypes.
Activation of A2B AR implies stimulation of adenylate
cyclase and activation of phospholipase C through the
coupling to Gs and Gq/11 proteins, respectively. A2B ARs
have been found on practically every cell in most species,
and their sequences are highly similar across species. The
human (h) A2B AR shares, for example, 86–87% amino
acid sequence homology with the rat and mouse subtypes
[14]. Determination of receptor-coding messenger RNA
(mRNA) levels furnished important information about A2B
AR tissue distribution. High concentrations of A2B ARs
have been suggested in caecum, large intestine and urinary
bladder, whereas a lower expression has been revealed in
lung, blood vessels, eye, and mast cells. Adipose tissue,
adrenal gland, brain, kidney, liver, ovary and pituitary gland
are thought to have a very low concentration of A2B AR
[12].
A2B ARs are known as the most poorly characterised of
the adenosine P1 receptors from a pharmacological point of
view, as their general low affinity towards prototypic
ligands exerting specific high affinity and potency in
activating each of the remaining AR subtypes. In particular,
the scarcity of medicinal chemistry knowledge about the
structural requirements necessary for potent and selective
activation of the A2B AR subtype has created wide-ranging
difficulty in detecting the physiological effects mediated by
direct and selective A2B AR stimulation. Despite these
limitations, growing and promising information in under-
standing the physiological meaning of these receptors has
arisen from the exploitation of potency and selectivity of
288 Purinergic Signalling (2008) 4:287–303ligands for A1,A 2A and/or A3 ARs by employing a strategy
of exclusion in a model in which more AR subtypes are
coexpressed. The A2A AR-selective agonist CGS21680 has
been reported, for example, as a useful tool for differentiation
between A2A and A2B ARs [14]. Moreover, some potent and
selective antagonists of the A2B AR have been employed to
distinguish A2B AR-mediated effects. Until a few years ago,
the characterisation of A2B ARs through radioligand binding
studies using low-affinity and nonselective antagonists such
as [
3H]1,3-dipropyl-8-cyclopentyl-xanthine ([
3H]DPCPX),
[
3H](4-(2-[7-amino-2-(2-furyl)-[1,2,4]triazolo-[2,3-a][1,3,5]
triazin-5-ylamino] ethyl)-phenol ([
3H]ZM 241385), [
125I]3-
(3,4-aminobenzyl)-8-(4-oxyacetate)phenyl-1-propyl-xanthine
([
125I]ABOPX) [16]. A helpful advancement in the pharma-
cological characterisation of A2B A R si ss u p p o s e dt ob e
increased by the recent identification of the tritiated form of
some new A2B AR antagonists with improved potency and
selectivity, such as [
3H][N-(4-cyanophenyl)-2-[4-(2,3,6,7-
tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy]
acetamide ([
3H]MRS 1754) [17], [
3H]N-(2-(2-Phenyl-6-[4-
(2,2,3,3-tetratritrio-3-phenylpropyl)-piperazine-1-carbonyl]-
7Hpyrrolo[2,3-d]pyrimidin-4-ylamino)-ethyl)-acetamide
([
3H]OSIP339391) [18] and [
3H]N-benzo[1,3]dioxol-5-yl-2-
[5-(1,3-dipropyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)-
1-methyl-1H-pyrazol-3-yloxy]-acetamide ([
3H]MRE 2029-
F20) [19].
The contribution of genetic engineering and manipula-
tion (for example, generation of A2B AR knockout mice
and transgenic mice overexpressing this receptor), especial-
ly if combined with classic pharmacological investigations,
have determined relevant progress in establishing the
therapeutic potential of A2B AR ligands and, generally,
the role of ARs, in a variety of diseases [20–23].
A2B adenosine receptor physiology and pharmacology
The A2B AR subtype has been recognised to regulate a
wide range of physiopathological events. However, it is
mainly involved in modulating cardiovascular functions
and the genesis of inflammation processes. A role for A2B
AR in regulating vascular tone, cardiac myocyte contrac-
tility, neurosecretion and neurotransmission, cell growth,
gene expression, intestinal tone and secretion and mast-cell
function has been suggested [14]. A2B AR activation is
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1 2               3 [62]
rA1 (Ki) = 20.0 nM
rA2A (Ki) = 710 nM
hA2B (EC50) = 370 nM
hA3 (Ki) = 31.0 nM
              4 [62]
rA1 (Ki) = 30.0 nM
rA2A (Ki) = 50% at 1µM
hA2B (EC50) = 440 nM
hA3 (Ki) = 37.0 nM
              5 [62]
rA1 (Ki) = 30.0 nM
rA2A (Ki) =183 nM
hA2B (EC50) = 730 nM
hA3 (Ki) = 64.0 nM
       MRS3218 (6) [68]
hA1 (Ki) = 7.0 nM
hA2A (Ki) = 628 nM
hA2B (EC50) = 54.5 nM
hA3 (Ki) = 5.1 nM
Fig. 1 Adenosine (1), NECA
(2), N
6-substituted-adenosine
(3, 4) and NECA (5, 6) deriva-
tives as nonselective A2B AR
agonists
Purinergic Signalling (2008) 4:287–303 289known to induce angiogenesis [24–25], reduce vascular
permeabilisation [26], increase release of inflammatory
mediators from human and canine mast cells [24] and
modulate neurohypophysial hormone output [27]. Adeno-
sine, through A2B ARs, can exert long-term control over
glycogen levels in primary cultures of mouse cortical
astrocytes and might therefore play a significant role in
pathophysiological processes involving long-term modula-
tion of brain-energy metabolism [21]. There is evidence of
a probable involvement of A2B ARs in the growth and
development of some tumours , and A2B ARs have been
proposed as targets to control cell growth and proliferation
in a human breast cancer cell line [28].
ARs play a significant role in regulating ion transport in
epithelial tissues through a variety of intracellular signalling
pathways. Each of the four P1 receptors has distinctive
roles in different epithelial tissue types. The A2B AR has
been identified on both the mucosal and basolateral aspect
of colonic epithelial cells. Activation at either site results in
Cl- secretion via direct activation of the cAMP-activated
Cl
− channel cystic fibrosis transmembrane conductance
regulator (CFTR) [29]. An analogous process of adenosine-
mediated activation of Cl- secretion has been located at the
lung epithelium [30]. The stimulated secretory response has
been identified to be the result of A2B AR activation and
was lost in a cell line derived from a cystic fibrosis patient
with a defect in ion transport at CFTR, implicating this ion
channel as the one responsible for the A2B AR-mediated Cl-
secretion [31].
Therapeutic potential of A2B adenosine receptor
antagonists
There are growing findings supporting adenosine as having
a role in asthma and chronic obstructive pulmonary disease
(COPD) [32]. Moreover, adenosine stimulates production
of interleukin (IL)-4 and IL-13 in mast cells via A2B AR
activation [33]. Treatment of asthma with selective A2B AR
antagonists has so far been one of the most significant
therapeutic options among AR ligands [34–38].
A2BAR antagonists are directed towards clinical use for
treating diabetes, as these seem to antagonise the adenosine-
induced hepatic glucose production determining reduction of
blood glucose levels after oral administration [39]. A2B AR
h a sb e e nl i k e w i s er e p o r t e dt ob ei n v o l v e di ns t i m u l a t i n g
proliferation, differentiation and migration of retinal endo-
thelial cells. Thus A2B AR antagonists may offer a way to
inhibit retinal angiogenesis, providing a novel therapeutic
approach for treating diseases associated with aberrant
neovascularisation, such as diabetic retinopathy [40].
The opioid and adenosine systems seem to cooperate to
some extent in modulating pain signalling. In particular,
participation of A2B ARs in the analgaesic effects mediated
by caffeine in an acute animal model of nociception (hot-
plate test) has been documented [41]. These findings
support the potential therapeutic employment of specific
A2B AR antagonists as valuable adjuvant drugs for opioid
analgaesia, with minimal side effects.
The purinergic regulation of epithelial transports and,
above all, involvement of the A2B AR subtype in determining
secretion stimulation, suggest the possibility of employing
A2B AR-specific ligands as potential modulators of ion
transport and the parallel flux of water, which can be
considered a natural defence system working to “wash away”
injuries in the setting of cellular damage or inflammation.
Selective A2B AR ligands are under investigation for treating
diarrhoea and cystic fibrosis [42–44].
Therapeutic potential of A2B adenosine receptor
agonists
Ischaemic preconditioning (IPC) is a cardioprotective
mechanism according to which brief and repeated episodes
of sublethal ischaemia and reperfusion, before myocardial
infarction, cause the heart to become resistant to infarction
and result in attenuation of infarct size. Activation of
cardiac A2B AR receptors at reperfusion showed to be
protective in the rabbit, but because of the very low affinity
of the receptors, endogenous cardiac adenosine is unable to
elicit their signalling. Protein kinase C physiologically
increases the heart’s sensitivity to adenosine so that
endogenous adenosine can activate A2B AR-dependent
signalling. 2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl)
pyridin-2-ylsulfanyl]acetamide (BAY 60–6583), a highly
selective A2B AR agonist [45] (Fig. 3), resulted in limited
infarct size when given to rabbit-ischaemic hearts at
reperfusion [46]. Postconditioning protects the heart with
multiple brief reperfusion/ischaemia cycles immediately
following the ischaemic insult. In rabbit hearts, binding of
endogenous adenosine to A2B ARs in early reperfusion is a
requirement for both IPC and postconditioning to limit
infarction [47].
A pharmacological and gene-targeting approach per-
formed with mice models to study the contributions of AR
signalling to ischaemic preconditioning cardioprotection
provided evidence that selective A2B AR agonists may offer
important advantages in comparison with classical therapies
of acute myocardial ischaemia [48]. Intravenous adminis-
tration of nonselective adenosine is associated with side
effects (bradycardia, hypotension, rapid receptor desensiti-
sation), which could be circumvented by the use of specific
A2B AR agonists [23].
Deletion of the gene encoding the A2B AR in the mouse
(A2B AR-knockout mouse model) recently resulted in
290 Purinergic Signalling (2008) 4:287–303increased production of proinflammatory cytokines, altered
response to endotoxin exposure, increased leukocyte adhe-
sion and increased leukocyte rolling on blood vessels [49].
Activation of A2B AR subtype would moreover increase
production of the anti-inflammatory cytokine IL-10 [50].
The described association of A2B AR with pre/postcondi-
tioning cardioprotection, along with the documented strong
anti-inflammatory role of A2B AR signalling [49], suggests
that A2B AR agonists may represent a new group of
therapeutics for patients suffering from coronary artery
disease. Several reports contribute to strengthen this per-
spective, highlighting essential A2B AR-mediated cardiovas-
cular effects. A NECA-mediated coronary vasodilation via
the A2B AR subtype in isolated hearts from young (1–
2m o n t h s )a n dm a t u r e( 1 2 –18 months) Wistar rats has been
documented [51]. Adenosine-mediated vasorelaxation in
mouse aorta is partially dependent on A2B AR [52], and
A2B ARs mediate relaxation in human small resistance-like
coronary arteries, which is independent of nitric oxide (NO)
but partly coupled to potassium (K
+) channel function [53].
Human aortic smooth muscle cells (SMCs) synthesise
adenosine, which seems to protect against vasoocclusive
disorders by inhibiting SMC proliferation and collagen
synthesis via activation of A2B AR receptors [54]. Apoptosis
of arterial smooth muscle cells (ASMCs) could play an
important role in the pathogenesis of atherosclerosis and
restenosis. Recent results indicate that adenosine-induced
apoptosis of cultured human ASMCs is essentially mediated
via A2B AR and involves a cAMP-dependent pathway [55].
These studies speculated that adenosine could play a dual role
in the evolution of intimal thickening. Its action can be
considered beneficial concerning control of intimal hyperpla-
sia and thickening formation. In contrast, the same authors
indicated that adenosine could contribute to the formation of
the necrotic core in advanced atherosclerotic lesions, promot-
ing—along with other concurrent factors—plaque rupture.
These opposing effects suggest different therapeutic strategies
based on the role of A2B AR stimulation-mediated effects in
the pathogenesis of atherosclerosis and restenosis.
Glomerular mesangial cell (GMC) growth is inhibited by
A2B AR activation coupled with inhibition of mitogen-
activated protein kinase (MAPK) activity [56]. A2B AR
function may therefore largely affect glomerular remodeling
associated with GMC proliferation. Identification of phar-
macological agents able to specifically activate A2B ARs
has been purported to be of therapeutic importance in
protecting against glomerular remodeling associated with
glomerulosclerosis, renal disease and abnormal GMC
growth associated with hypertension and diabetes.
Studies performed by the Shiseido Research Group
indicate that adenosine, via A2B AR, might stimulate hair
growth through fibroblast growth factor-7 gene expression
upregulation in dermal papilla cells [57].
In the research field concerning vasculogenic erectile
dysfunctions, there emerged key importance regarding
purinergic transmission for initiating and maintaining penile
erection [58]. Endothelial dysfunction of human corpus
cavernosum may be correlated with the loss of adenosine
A2B ARs activity, indicating a possible employment of
specific A2B AR agonists as anew therapeutic approach to
manage severe vasculogenic impotence resistant to com-
mon vasodilators [59].
As interaction of adenosine with A2B ARs inhibits
production of the proinflammatory cytokine tumor necrosis
factor (TNFα) by lipopolysaccharide-activated monocytes
[49, 60], A2B AR agonists have been proposed for treating
septic shock, confirming the broad anti-inflammatory poten-
tial of AR agonists in treating inflammatory disorders [61].
A2B adenosine receptor agonists
The lack of molecules endowed with selective and potent
agonistic activity towards the hA2B ARs has limited the
studies on this pharmacological target and consequently the
evaluation of its therapeutic potential. Several ligands for
A2B AR have been identified in recent years [62–64].
However, only very recently have some reports about
important advancement in identifying A2B AR agonists with
improved in vitro pharmacological profile been published.
Medicinal chemistry literature concerning the field of
AR agonists is generally characterised by the absence of
binding data related to the A2B AR subtype, caused by the
substantial lack of a useful radiolabelled agonist. Therefore,
for the time being, the selectivity profile of new potential
A2B AR agonists can only be speculated in view of the ratio
of binding parameters (Ki values for A1,A 2A,A 3 ARs) to
functional parameters (EC50 for A2B, Tables 1, 2, 3, 4, 5,
and 6).
The compounds of particular interest for the develop-
ment of potent and selective A2B AR agonists can be
classified into adenosine-like and nonadenosine-like
ligands. Nucleoside-based agonists are the result of modi-
fying the endogenous ligand, adenosine, by substitution at
the N
6-, C
2-positions of the purine heterocycle and/or at the
5′-position of the ribose moiety. In particular, the most
potent and subtype-selective ligands have been obtained by
combining these substitutions (i.e., multiply substituted
adenosines). This group can be subdivided into the following
subclasses: N
6-substituted adenosines, N
6-substituted-5′-N-
alkyl-carboxamidoadenosines, C
2-substituted adenosines and
C
2-substituted-5′-N-alkyl-carboxamidoadenosines.
Nonadenosine derivatives so far reported are represented
by conveniently substituted pyridine-3,5-dicarbonitrile
derivatives.
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In the search for A2B AR agonists, de Zwart et al. reported
a functional screening, based on adenylate cyclase stimu-
lation, of known adenosine analogues variously modified at
the 2-, 5-, 8-, N
6 and 5′ positions (or combinations of these)
[65]. This study indicated NECA (5′-N-carboxamidoadeno-
sine, 2, Fig. 1) as the most potent ligand since then
reported. More generally, after these first studies, the 5′-N-
carboxamidoadenosines seemed more potent than the
corresponding 4′-CH2OH derivatives, N
6-substitution
showed higher compatibility with A2B AR subtype com-
pared with C
2- and/or C
8- substitutions and deazapurine
derivatives resulted as inactive. Thus, N
6-substituted-5′-N-
carboxamidoadenosine derivatives were initially considered
as the most promising tool for identifying A2B AR agonists.
More recently, a series of carboxamido and thiocarboxami-
doadenosines bearing several 5′-N-(cyclo)alkyl groups [66]
have been synthesised and tested at the four AR subtypes.
The replacement of the 5′-N-ethyl carboxamido function of
NECA with other alkyl groups or the thiocarboxamido
moiety led to a significant loss of A2B AR potency and, in
some examples, to reduced intrinsic activity (data not
shown).
N
6-substitution
Some examples of N
6-substituted adenosine derivatives
endowed with satisfactory levels of A2B AR potency have
been reported [62]. In particular, the introduction of
(substituted) phenyl rings at the N
6-position led to the
identification of compounds such as the 4-I-phenyl and 4-
aminosulfonylphenyl derivatives 3 and 4 (Fig. 1) displaying
submicromolar potency in activating the A2B AR subtype
[64]. N
6-modification of NECA with substituted phenyl
N
N N
N
HN
O
OH OH
H
NO
R
O
N
H
O
R’
Table 1 Binding affinities (hA1,h A 2A,h A 3 ) and functional parameters (hA2B) of the N
6-(hetero)aryl-carbamoyl-methoxy-phenyl)-(2-chloro)-
NECA derivatives 7–18 at the human adenosine receptors expressed in CHO cells [69]
RR ′ hA1
a Ki (nM) hA2A
b Ki (nM) hA2B
c EC50 (nM) hA3
d Ki (nM)
NECA 18.2±2.1 12.4±2.7 155±12 35.7±3.3
7 H Ph 8.5±0.8 >1000 (45%) 7.3±0.6 38.4±3.7
8 H 4-F-Ph 2.3±0.2 >1000 (48%) 15.2±2.1 72.3±7.4
9 H 4-Cl-Ph 3.1±0.3 >1000 (35%) 12.3±1.4 34.2±3.7
10 H 4-Br-Ph 3.5±0.4 >1000 (26%) 10.5±1.2 36.4±3.7
11 H 4-I-Ph 5.2±0.5 >1000 (28%) 30.2±2.8 85.2±8.3
12 H 4-OCH3-Ph 4.7±0.4 >1000 (42%) 32.4±3.3 25.3±2.6
13 H 3,4-OCH2O-Ph 8.4±0.9 >1000 (5%) 35.5±2.7 81.4±8.3
14 H 4-tert-Butyl-Ph 18.6±2.1 >1000 (1%) 16.4±2.1 40.2±3.9
15 H 4-Pyridyl 11.2±1.3 >1000 (37%) 32.3±2.4 42.3±4.7
16 H Benzyl 20.4±2.1 >1000 (49%) 150±17 82.7±8.9
17 Cl Ph 30.5±3.3 >1000 (36%) 42.6±4.2 107±10
18 Cl Benzyl 22.6±2.4 >1000 (49%) 175±14 75.7±7.4
aDisplacement of specific [
3H]CHA binding at human A1 receptors expressed in CHO cells.
bDisplacement of specific [
3H]CGS21680 binding
at human A2A receptors expressed in CHO cells. In parentheses are indicated the percentage of displacement of the examined compounds (1 μM).
ccAMP assay in CHO cells expressing human A2B adenosine receptors EC50 (nM).
dDisplacement of specific [
125I]ABMECA binding at human
A3 receptors expressed in CHO cells. Data are expressed as geometric means with 95% confidence limits.
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the corresponding adenosine analogues (N
6-(4-chlorophenyl)
NECA, 5,E C 50=0.73 μM) [67]. In a recent study of
modelling and site-directed mutagenesis performed with the
aim of defining the leading parameters affecting the
interaction between A2A AR and its specific agonists [68],
the N
6-guanidino derivative 6 of NECA (Fig. 1) was
identified. Replacement of the 6-amino group of NECAwith
the guanidino moiety determined a threefold enhancement in
A2B AR activation potency (EC50=54.5 nM versus 140 nM
of NECA) and an increased selectivity versus A2A AR
subtype (Ki=628 nM versus 2.2 nM), maintaining a high
affinity at the A3 (Ki=5.1 nM) and A1ARs (Ki=7.0 nM).
The disubstitution of the amino group at the 6-position
of adenosine is not tolerated by A2B AR subtype (data not
shown) [64].
A novel series of potent but low-selective A2B AR
agonists structurally related to NECA has been recently
reported by Baraldi et al. [69]. These compounds were
designed modifying the N
6-position of 5′-N-carboxamidoa-
denosine in analogy with the typical substitution pattern of
some potent and selective A2B AR antagonists previously
reported in the literature. Several A2B AR antagonists with
high affinity and good selectivity have, in fact, been
identified among structures based upon a xanthine core
suitably substituted at the 1-, 3- and 8-positions [70]. In
particular, Kim et al. [71] reported that a (substituted)
phenylcarbamoyl-methoxy-phenyl chain at the 8-position
of a series of 1,3-dipropyl-xanthines was able to specifi-
cally direct the antagonist activity to the A2B AR. Further
evidence of the important role of the substituent at the 8-
position as the structural selectivity element for the design
of potent A2B AR antagonists was provided recently by our
group [72].
Considering the previous structure activity relationship
(SAR) studies, regarding NECA and adenosine derivatives
indicating the N
6 as a useful position for A2B AR binding-
site recognition, a new series of N
6-[(substituted)phenyl/
cycloalkyl/benzyl/heteroaryl- carbamoyl-methoxy-phenyl]-
5′-N ethylcarboxamido- adenosine and 2-chloro-adenosine
derivatives (7–18,T a b l e1) has been designed and
synthesised. These molecules can be considered as molec-
ular hybrids obtained by the introduction of an aryl-
carbamoyl-methoxy-phenyl chain (supposed to grant A2B
N
N N
N
NH
O
OH OH
H
NO
R
HN
R’ O
Table 2 Binding affinities (hA1,h A 2A,h A 3) and functional parameters (hA2B) of the 6-(heteroaryl-carbonyl)-hydrazino-NECA derivatives 19–26
at the human adenosine receptors expressed in CHO cells [79, 80]
RR ′ hA1
a Ki (nM) hA2A
b Ki (nM) hA2B
c EC50 (nM) hA3
d Ki (nM)
NECA 18.3±2.5 12.5±2.8 160±20 34.6±3.3
19 H 2-Furyl 1050±132 1550±165 82±10 > 5000 (23%)
20 H 5-Bromo-furan-2-yl 780±34 1200±135 369±42 > 5000 (13%)
21 H 5-Methyl-furan-2-yl 700±25 1600±147 227±18 > 5000 (15%)
22 H 5-Methyl-thiophen-2-yl 1100±124 2100±185 273±12 > 5000 (19%)
23 Cl 2-Furyl 3500±275 4950±356 210±13 > 5000 (26%)
24 Cl 5-Methyl-thiophen-2-yl 2600±194 4100±390 175±20 > 5000 (17%)
25 Cl Thiophen-3-yl 933±76 3300±315 450±29 > 5000 (18%)
26 Cl Thiophen-2-yl 737±46 1700±180 200±20 > 5000 (12%)
aDisplacement of specific [
3H]CHA binding at human A1 receptors expressed in CHO cells.
bDisplacement of specific [
3H]CGS21680 binding
at human A2A receptors expressed in CHO cells.
ccAMP assay in CHO cells expressing human A2B adenosine receptors EC50 (nM).
dDisplacement of specific [
125I]ABMECA binding at human A3 receptors expressed in CHO cells. The percentages in the parentheses indicate
the % of displacement of the new tested compounds in the binding experiments (5 μM). Data are expressed as geometric means with 95%
confidence limits. The data are expressed as mean ± SEM.
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at the N
6-position of the typical nucleoside nucleus
responsible for AR activation. The key role of this position
in the formation of the A2B AR-ligand complex has been
confirmed by a molecular modelling investigation per-
formed with the human A2B AR. The docking of known
A2B AR agonists highlighted, in fact, involvement of the
exocyclic amino group at the 6-position of NECA in an
important interaction with a residue of asparagine 254
belonging to the VI transmembrane receptor helix [73]. The
2-chloro atom was introduced, as the literature in the field
of A2B AR agonists indicates the 2-position as a second
possible site of modification of the purine nucleus [74].
As described in Table 1, different kinds of substitutions
have been considered at the nitrogen atom of the acetamide
chain introduced at the N
6-position of NECA. All synthes-
ised compounds were evaluated in radioligand-binding
assays to define their affinities for human A1,A 2A and A3
N
N N
N
NH
O
OH OH
R''
R
R'
Table 3 Binding affinities (A1,A 2A,A 3) and functional parameters (A2B) of 2-substituted adenosine and NECA derivatives 27–38 at the
adenosine receptors
RR ′ R″ A1
a Ki nM A2A
b Ki
nM
A2B
c EC50
μM
A3
d Ki nM
2-Cl-Ado (27) [62,65]C l H C H 2OH 9.3
e 63.0
f 24.0 1,890
g
(R,S)PHPAdo (28) [81]- C ≡C-CH(OH)Ph H CH2OH 0.67
(0.55–0.80)
7.0
(3.7–13)
2.4
(1.5–3.7)
3.3
(2.3–4.8)
(R)PHPAdo LUF5599 (29) [81]- C ≡C-CH(OH)Ph H CH2OH 0.44
(0.38–0.52)
29.0
(19–45)
6.2
(2.9–13)
5.0
(3.2–7.7)
(S)PHPAdo LUF 5600 (30) [81]- C ≡C-CH(OH)Ph H CH2OH 0.67
(0.47–0.96)
1.8
(1.1–3.0)
0.92
(0.71–1.2)
1.4
(0.78–2.4)
N
6-ethyl-(R,S)PHPAdo (31) [82]- C ≡C-CH(OH)Ph Et CH2OH 2.7
(2.4–2.9)
94.0
(72–123)
1.7
(0.97–3.0)
0.97
(0.58–1.6)
(R,S)PHPNECA (32) [74]- C ≡C-CH(OH)Ph H CONHEt 2.7
(1.2–3.7)
3.1
(2.4–3.9)
1.1
(0.47–2.6)
0.42
(0.17–1.0)
(R)PHPNECA (33) [74]- C ≡C-CH(OH)Ph H CONHEt 1.9
(1.8–2.1)
39.0
(25–59)
2.4
(1.5–3.8)
5.5
(3.6–8.5)
(S)PHPNECA (34) [74]- C ≡C-CH(OH)Ph H CONHEt 2.1
(1.2–3.7)
2.0
(1.2–3.5)
0.22
(0.22–0.23)
0.75
(0.52–1.1)
N
6-ethyl-(R,S)PHPNECA (35) [74]- C ≡C-CH(OH)Ph Et CONHEt 15
(8.0–29)
90
(48–170)
2.0
(1.3–3.2)
2.1
(1.3–4.4)
(R,S)-2-(3-hydroxy-1-pentynyl)
NECA (36) [62]
-C≡C-CH(OH)Et H CONHEt 4.1 3.1 1.3 1.0
(R,S)-2-(4-hydroxy-1-pentynyl)
NECA (37) [62]
-C≡C-CH2CH(OH)CH3 H CONHEt 40.0
(26–62)
14.0
(10–20)
13.3 4.1
(3.4–4.9)
(R,S)PHPMECA (38) [74]- C ≡C-CH(OH)Ph H CONHCH3 14.0
(8.7–22)
3.1
(1.7–5.4)
5.0
(3.5–7.2)
1.7
(1.0–2.7)
aDisplacement of specific [
3H]CCPA binding in CHO cells stably transfected with human recombinant A1 adenosine receptor, expressed as Ki
(nM), unless noted.
b Displacement of specific [
3H]NECA binding in CHO cells stably transfected with human recombinant A2A adenosine
receptor, expressed as Ki (nM), unless noted.
cMeasurement of receptor-stimulated adenylyl cyclase activity in CHO cells stably transfected with
human recombinant A2B adenosine receptor, expressed as EC50 (μM).
dDisplacement of specific [
3H]NECA binding in CHO cells stably
transfected with human recombinant A3 adenosine receptor, expressed as Ki (nM), unless noted.
eDisplacement of [
3H]PIA binding from rat brain
membranes.
f Displacement of [
3H]CGS21680 from rat striatal membranes.
gDisplacement of [
125I]APNEA binding in CHO cells stably
transfected with the rat A3-cDNA.
294 Purinergic Signalling (2008) 4:287–303ARs. The compounds were also evaluated in a functional
assay, measuring their capacity to modulate cAMP levels in
CHO cells expressing hA2B AR receptors. The compounds
were shown to bind the adenosine A1 receptor (Ki-binding
values ranging from 2.3 to 30.5 nM) and to activate the
adenosine A2B AR (EC50 values ranging from 7.3 to
175 nM) in the low nanomolar range, displaying at the
same time a considerable level of selectivity toward A2A
AR subtypes (Ki>1 μM) and a relevant capability to bind
A3 ARs.
Substitution at the paraposition of the phenyl ring with a
halogen atom led to a two- to fourfold loss of A2B AR
N
N N
N
NH2
O
OH OH
HO
O
R
Table 4 Binding affinities (hA1,h A 2A,h A 3) and functional parameters (hA2B) of 2-(hetero)arylethyloxy-adenosine derivatives 39–47 at the
human adenosine receptors [85, 86]
Rh A 1
a Ki nM hA2A
b Ki nM hA2B
c EC50 nM hA3
d Ki nM
NECA 6.8±2.4 2.2±0.6 140±19 16.0±5.4
39 Ph 221±57 9.3±2.9 3490±1490 54.2±14.3
40 2-naphthyl 141±51 16.1±7.0 1440±70 130±8
41 2-thienyl 174±20 10.9±4.8 1780±260 93.3±16.8
MRS3534 (42) 3-indolyl 148±19 45.0±11.6 299±45 232±54
43 3-(5-F-indolyl) 150±50 370±80 767 490±60
44 3-(6-Cl-indolyl) 145±6 29.3±13.7 216±59 92.3±7.9
MRS3997 (45) 3-(6-Br-indolyl) 253±3 150±20 128±32 90±15
MRS3854 (46) 3-(5-Br-indolyl) 358±1 502±32 365±73 234±24
47 3-(5-OH-indolyl) 310±90 450±8 896 120±20
aDisplacement of specific [
3H]CCPA binding, membranes from CHO cells stably transfected with human recombinant A1 adenosine receptor, Ki
(nM).
bDisplacement of specific [
3H]CGS21680 binding, membranes from HEK-293 cells stably transfected with human recombinant A2A
adenosine receptor, Ki (nM).
ccAMP assay in CHO cells expressing human A2B adenosine receptors, EC50 (nM).
dDisplacement of specific [
125I]
ABMECA binding, membranes from CHO cells stably transfected with human recombinant A3 adenosine receptor, Ki (nM).
N
NC CN
H2N
R
S
N
H
N
Table 5 Binding affinities (hA1,h A 2A,h A 3), functional parameters (hA2B) and percentages of efficacy of the 2-amino-6-(1H-imidazol-2-
ylmethylsulfanyl)-4-(substituted)phenyl pyridine-3,5-dicarbonitrile derivatives 48–52 as AR agonists and partial agonists [88]
Rh A 1
a Ki nM
(efficacy, %)
hA2A
b Ki nM
(efficacy, %)
hA2B
c EC50 nM
(efficacy, %)
hA3
d Ki nM
(efficacy, %)
NECA 12 (9.6–15) 60±10 104±15 11±0.8
LUF 5833 (48) Phenyl 2.4±1.0(109) 28±4(55) 19±7(81) 171±109(84)
LUF 5834(49) p-OH-phenyl 2.6±0.3(103) 28±4(55) 12±2(74) 538±210(23)
LUF 5835(50) m-OH-phenyl 4.4±2.0(112) 21±2(80) 10±3(92) 104±49(95)
LUF 5844(51) m-OCH3-phenyl 2.0±1.0(80) 105±22(49) 34±24(68) 74±21(39)
LUF 5845(52) p-OCH3-phenyl 7.0±0.8(46) 214±37(32) 9±3(33) 24±7.6(73)
aDisplacement of specific [
3H]DPCPX binding at human A1 receptors expressed in CHO cells.
bDisplacement of specific [
3H]ZM241385
binding at human A2A receptors expressed in HEK293 cells.
ccAMP assay in CHO cells expressing human A2B adenosine receptors EC50 (nM).
dDisplacement of specific [
125I]ABMECA binding at human A3 receptors expressed in HEK293 cells.
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derivative 7 (EC50 hA2B=7.3 nM). The same behaviour
has been observed by introducing functions with reverse
electronic effects, such as the 4-methoxy group (12,E C 50
hA2B=32.4 nM). Conversely, increasing the steric hin-
drance around the paraposition by introducing a tert-butyl
led to obtaining a very potent agonist for the A2B AR
(compound 14), with an EC50 value comparable with that
of the unsubstituted phenyl derivative 7. Replacement of
the phenyl with the 4-pyridyl moiety resulted in a fourfold
decrease in the potency (15,E C 50 hA2B=32.3 nM). The
presence of a chlorine atom at the 2-position had a slightly
detrimental effect in terms of A2B AR activation, as
emerged from the comparison of the biological data of the
2-chloro derivatives with the corresponding 2-unsubstituted
compounds. Considering the binding and functional profile
of NECA [69] (Table 1) and (S)-PHPNECA [74]( Ki hA1=
2.1 nM; Ki hA2A=2.0 nM; EC50 hA2B=220 nM; Ki hA3=
0.75 nM), which are among the most potent adenosine-like
A2B AR agonists previously reported, these molecules
represent a remarkable advance in the search for potent
A2B AR agonists, albeit the selectivity profile must be
undoubtedly improved. Most of the examined molecules, in
fact, preferentially bound to the A1 receptor, with Ki
binding values ranging from 2.3 to 30.5 nM. This
experimental observation can be explained in light of the
literature, indicating that A1 AR selectivity is enhanced by
monosubstitution of the exocyclic amino group at the 6-
position of adenosine with bulky cycloalkyl or arylalkyl
substituents [75]. A lower, but significant, affinity for the
A3 AR was observed. The most selective compounds
versus A3 AR subtype were the unsubstituted phenyl
derivative (7) and the 4-halo-phenyl derivatives (8–11).
The cAMP functional assay tested that the designed
molecules behave as full A2B AR agonists. These com-
pounds represent, to the best of our knowledge, the first
report about adenosine-related structures capable of acti-
vating hA2B AR subtype in the very low nanomolar range.
In the search for nucleoside-based ligands for ARs,
some N
6-carboxamido derivatives of adenosine-5′-N-
ethyluronamide (NECA) have been synthesised and tested
in binding and/or functional assays at the four known AR
subtypes exerting a general behaviour as low-selective A1
AR ligands [76]. Some N
6-(substituted-phenylcarbamoyl)-
derivatives of NECA were instead found to have affinity at
rat A3 ARs in the low nanomolar range, with different
degrees of selectivity versus A1 and A2A ARs [77, 78].
These results indicated that small modifications of the chain
at the 6-position of the purine nucleus can produce
significant changes in the selectivity pattern of potential
AR ligands. According to the principles of bioisosterism,
the (hetero)aryl-urea function of the reported A3 AR
agonists has been recently replaced with the isomeric
(hetero)aryl-carbonyl-hydrazino moiety, and the effect on
binding and functional profile of the synthesised com-
pounds has been evaluated [79, 80]. The coexisting effect
of substitution at the 2-position of the purine with a
chlorine atom has also been examined. Competition-
binding experiments were performed to evaluate the affinity
of the synthesised compounds to hA1,h A 2A and hA3 ARs
expressed in CHO cells using as radioligands [
3H]-CHA,
[
3H]-CGS 21680 and [
125I]-AB-MECA, respectively. The
compounds were also evaluated in functional assays,
measuring their capacity to modulate cAMP levels in
CHO cells expressing hA2B ARs. Structures and biological
data of a selection of the synthesised compounds are listed
in Table 2.
The series has been developed introducing different
(substituted) heteroaryl nuclei on the N
6-hydrazide chain.
The new class of 1-deoxy-1-[6-[((hetero)aryl-carbonyl)-
hydrazino]-9H-purin-9-yl]-N-ethyl-β-D-ribofuranuronamide
and 1-deoxy-1-[2-chloro-6-[((hetero)aryl-carbonyl)-
hydrazino]-9H-purin-9-yl]-N-ethyl-β-D-ribofuranuronamide
derivatives have been found to be the first examples of both
potent and selective A2B AR agonists showing considerable
potency in activating A2B ARs, with EC50 values ranging
from 82 to 450 nM. The most innovative finding rests in the
analysis of the selectivity information emerging from the
comparison between affinity and functional data related to
the four AR subtypes. Of the examined molecules, the ones
showing the capability to activate A2B ARs were inactive at
the hA3 AR (Ki>5,000 nM) and showed high nanomolar-
micromolar affinity at the A1 and A2A AR subtypes (Ki
varying from 700 to 5,000 nM). In particular, compound 1-
deoxy-1-{6-[N′-(furan-2-carbonyl)-hydrazino]-9H-purin-9-
yl}-N-ethyl-β-D-ribofuranuronamide (19,h A 1,hA2A Ki>
1,000 nM; hA2B EC50=82 nM, hA3 Ki>5,000 nM) was the
most potent of the series, and it was confirmed to be a full
Table 6 Potency of 2-amino-
4-(substituted)phenyl pyridine-
3,5-dicarbonitrile derivatives
53–56 and BAY-60–6583 in
activating ARs
hA1 cAMP
assay EC50 nM
hA2A cAMP
assay EC50 nM
hA2B cAMP
assay EC50 nM
hA3 cAMP
assay EC50 nM
53 [89] 0.2 236 0.1 –
54 [89] 0.7 103 0.5 –
55 [89] 0.4 142 0.3 –
56 [89] 0.3 1200 1.4 –
BAY-60–6583 (58) [45, 46] >10,000 >10,000 3 nM >10,000
296 Purinergic Signalling (2008) 4:287–303agonist in a functional assay based on the measurement of its
capacity to modulate cAMP levels in CHO cells expressing
hA2B AR (Fig. 2). Nevertheless, both furan and thiophene
rings were shown to exert similar favourable interactions for
receptor activation [compare furan derivatives, 21 (hA2B
EC50=227 nM) and 23, with the related thiophene deriva-
tives 22 (hA2B EC50=273 nM) and 26]. The presence of the
chlorine atom at the 2-position of the purine nucleus did not
seem to affect the ability of the tested compounds to activate
hA2B AR, as is clear from the comparison of chlorinated
derivatives 23 (hA2B EC50=210 nM) and 24 (hA2B EC50=
175 nM) with the corresponding nonchlorinated 19 (hA2B
EC50=82 nM) and 22 (hA2B EC50=273 nM). The examined
molecules can be considered valuable tools for the design
and development of new and even more selective and potent
ligands.
C
2-substitution
The introductionof a bulky substituent at the 2-position ofthe
adenine ring of NECA is known to induce A2A AR-selective
agonistic activity. CGS21680 has, in fact, been considered
one of the most potent A2A AR agonist and the ligand of
choice to distinguish A2A-a n dA 2B AR-mediated effects (Ki
values from binding assays for hA1,h A 2A and hA3 AR
subtypes of 298, 27 and 67 nM respectively; EC50 value
from stimulation of adenylyl cyclase activity through A2B
AR of 88.8 μM) [11]. The first attempts to substitute the
2-position of adenosine indicated that A2B AR did not
tolerate well such structural modulation [65]. An appreciable
improvement of A2B AR affinity has, however, bgeem
recognised, introducing a 2-chloro atom (2-ClAdo, 27,
Table 3,E C 50 from measurement of receptor-stimulated
adenylate cyclase activity in CHO, stably transfected with
hA2B AR of 24 μM) or 2-alkynyl chains. The racemic 2-
phenylhydroxypropynyladenosine [(R,S)-PHPAdo, 28][ 15]
had been found to exert activity at A2B AR comparable with
that of NECA (EC50=2.4 μM). The (R)d i a s t e r e o m e ro f
PHPAdo (LUF 5599, 29,E C 50=6.2 μM) was almost
sevenfold less potent than the (S) optical isomer (LUF
5600, 30,E C 50=0.92 μM). The introduction of small alkyl
chains at the N
6 position of (R,S)-PHPAdo was shown to be
tolerated for interaction with A2B AR, whereas large groups
abolished A2B AR potency (data not shown) [81]. In
particular, for N
6-ethyl-(R,S)-PHPAdo (31), an EC50 from
adenylyl cyclase assay of 1.7 μM has been reported [82].
Substitution of the 2-position of NECA with alkynyl chains
results in an increase of A2B AR affinity, as demonstrated by
the compound named 2-phenylhydroxypropynyl-5′-N-ethyl-
carboxamidoadenosine (PHPNECA, 32) displaying agonistic
activity in a functional assay at this AR subtype, with an
EC50 value of 1.1 μM[ 83]. The racemic (R,S)-PHPNECA
resulted in a twofold greater potency than the optically pure
(R)-PHPNECA (33,h A 2B EC50=2.4 μM) and a five fold
smaller potency than the (S)d i a s t e r e o m e r( 34,h A 2B EC50=
0.22 μM). (S)-PHPNECA was, therefore, 11-fold more
active than (R)-PHPNECA. The combination of the
N
6-a n d5 ′ substitutions as in compound N
6-ethyl-2-phenyl-
hydroxypropynyl-5′-N-ethylcarboxamidoadenosine 35 (hA2B
EC50=2.0 μM) led to decreased affinity for A2B AR [74].
Displacement of the phenyl ring of the alkynyl group had no
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Fig. 2 Dose-response curve of NECA and compound 19 on cAMP
assays in hA2B AR CHO cells
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Fig. 3 2-Amino-4-(substituted)phenyl pyridine-3,5-dicarbonitrile
derivatives: novel A2B AR agonists of particular interests for their
potential therapeutic applications
Purinergic Signalling (2008) 4:287–303 297effect on binding, as demonstrated by derivative (R,S)-2-(3-
hydroxy-1-pentynyl) NECA 36, which was as potent as (R,
S)-PHPNECA in activating A2B AR subtype (hA2B EC50=
1.3 μM). The presence of a hydroxyl group in α to the triple
bond appeared to be important for activity. The (R,S)-2-(4-
hydroxy-1-pentynyl) NECA 37, bearing a hydroxyl group in
β to the triple bond, was, in fact, 12-fold less potent than (R,
S)-PHPNECA (hA2B EC50=13.3 μM) [62]. The 5′-methyl-
carboxamido analogue of (R,S)-PHPNECA ((R,S)-
PHPMECA, 38) was 4.5-fold less active than the parent
compound (hA2B EC50=5.0 μM) [74].
A computational molecular docking of an heterogeneous
set of 46 known adenosine-like AR agonists, based on the
molecular models of the 3D structure of the four known AR
subtypes, was recently performed [84]. Comparison be-
tween the putative ligand-receptor complexes for each
receptor subtype suggested a general agonist-binding mode,
along with possible explanations for the differences in
agonist activities and AR selectivities. Some interesting
estimations about the binding mode of agonists at the A2B
AR subtype have been highlighted, with particular attention
to PHPNECA and its 2-hydroxypropynyl-substituted con-
geners. Specifically, the supposed orientations of ligands
inside the AR binding sites suggested that, in general, the
A2A and A2B AR subtypes have a smaller volume of the
putative hydrophobic pocket surrounding the 5′-N-alkyl
substituent than the A1 and A3 ARs. That gave a possible
explanation for the decreased affinity characterising car-
boxamido derivatives in which sterically demanding alkyl
groups were introduced at the 5′-N-position. Comparative
analysis of the different binding modes of optical isomers of
the 2-hydroxypropynyl-substituted agonists led to suppose a
critical involvement of the orientation of the hydroxyl group,
which resulted in affecting the capability to establish key H-
bond interactions with the binding site. Specifically, the
proposed binding mode of PHPNECA gave a rational
explanation for the higher affinity of the (S)-PHPNECA in
comparison with its (R) diastereomer, demonstrating that the
hydroxyl group of the (S)-phenylhydroxypropynyl fragment
could be hydrogen bonded to a cysteine residue located in
the second extracellular loop. On the contrary, the hydroxyl
group of the (R)-phenylhydroxypropynyl chain seems to be
surrounded by hydrophobic residues of Leu and Ala, thus
resulting in unfavourable ligand-receptor interactions.
In a recent study by Jacobson et al. [85], a wide series of
2-substituted adenosine derivatives was evaluated for their
affinity and efficacy through radioligand binding and
cAMP functional assays in intact CHO cells at the four
AR subtypes. This study included different 2-(cyclo)alkoxy,
2-(substituted/hetero)arylalkyloxy, 2-phenethylamino and
2-phenethylsulfanyl substitutions of adenosine. Most of
these compounds were found to be extremely weak at the
A2B AR; nevertheless, 2-(phenylethyloxy)adenosine 39
(Table 4,E C 50=3.49 μM), 2-[2-(2-naphthyl)ethyloxy]aden-
osine 40 (EC50=1.44 μM) and 2-[2-(2-thienyl)ethyloxy]
adenosine 41 (EC50=1.78 μM) have been reported to be
moderately potent A2BAR agonists. Based on the findings
that among these molecules, specific 2-(2-aryethyloxy)ether
derivatives also displayed significant activity at the A2B AR
subtype and that 2-ethers were more potent than the
corresponding amines or thioethers, the same authors
subsequently reported on a structure–activity relationship
study of 2,N
6,5′-substituted adenosine derivatives, which
led to the identification of compounds with enhanced
potency at the A2B AR and reduced potency at the other
AR subtypes [86]. In particular, 2-(3-indolyl)ethyloxy)
adenosines substituted at the 5″ or 6″ positions of the 2-
indole moiety with halogens or a hydroxyl function exerted
micromolar potency in activating A2B AR (EC50 values
from cAMP functional assay ranging from 0.128 to 1 μM),
with slightly improved selectivity versus the other AR
subtypes in comparison with previously reported reference
compounds [NECA, (S)-PHPNECA and 6-guanidino-
NECA]. Structures and corresponding potency/affinity data
of a selected series of these compounds at the four known
AR subtypes are reported in Table 4. Compound 2-(3″-
indolylethyloxy)adenosine 42 was found to be a rather
potent agonist at the hA2B AR (EC50=299 nM), although
the selectivity profile was not so satisfactory (Ki values at
A1,A 2A,A 3 ARs of 148, 45, 232 nM, respectively).
Substitution of the indole moiety with other (hetero)aryl
nuclei, such as phenyl, naphthyl, thiophene, pyrrole,
benzoimidazole or benzotriazole, did not succeed in
enhancing A2B AR potency. Elongation or branching of
the 2-alkyl spacer proved to weaken the affinity against all
ARs. 2-Indolyl derivative decreased markedly A2B AR
potency compared with 3-indolyl analogues, revealing that
altered connectivity failed to improve the binding profile of
the series (data not shown). The 5′-N-ethyluronamido
analogue of 42 was synthesised, considering that replacement
of the 4′-hydroxymethyl group with a 5′-N-ethylcarboxamido
function is generally known to favour A2B AR interaction.
Unexpectedly, in the 2-(3-indolyl)ethyloxyadenosine series,
this structural modification generated a threefold loss of
potency (EC50 hA2B=989 nM), hypothetically due to an
unfavourable change in the conformation of the ribose ring in
the ligand-binding site. Similar results were achieved intro-
ducing at the N
6-position of 42 an ethyl group (EC50 hA2B=
3,270 nM). Considering the potency of compound 42,t h e
authors replaced its 6-amino group with a N
6-guanidino
moiety detecting decreased potency at the A2B AR (hA2B=
40% of activation at 10 μM), along with reduced selectivity
versus A1 (Ki hA1=73.6 nM) and A3 (Ki hA3=90 nM) AR
subtypes. The best results in terms of A2B AR potency and
selectivity were achieved by substitution of the indole nucleus
of compound 42 with halogens (compounds 43–46,T a b l e4).
298 Purinergic Signalling (2008) 4:287–303In particular, the 6-bromo derivative 45 exerted higher
potency (EC50 hA2B=128 nM) and an improved binding
profile in comparison with NECA and (S)-PHP-NECA in
activating A2B AR, (hA1 Ki /hA2B EC50=1.97, hA2A Ki /
hA2B EC50=1.17, hA3 Ki /hA2B EC50=0.7). Activation
curves of this compound denoted a behaviour as partial
agonist at the hA1 and hA3 ARs and as full agonist at A2A
and A2B AR subtypes (data not shown). A molecular
modeling investigation performed by docking compound 2-
(3″-(6″-bromo-indolyl)ethyloxy)adenosine 45 in the rhodop-
sin-based molecular model of the human A2B AR gave
rational explanations for the experimental pharmacological
results, indicating that all the interactions previously proposed
for adenosine could be strengthen by favourable interactions
of the 2-(6-bromoindol-3-yl)ethyloxy chain with a distal
region of agonist-receptor-binding site. Moreover, the 2-
oxygen atom seemed to be involved in H bonding, with a
residue of Asn, whereas the NH of the indole ring seemed in
proximity of the OH of a residue of Ser, with which a
hydrogen bond, even not fully detected, cannot be excluded.
Nonadenosine agonists
Based on some patent claims concerning the synthesis of a
series of substituted 2-amino-4-phenyl-6-phenylsulfanylpyr-
idine-3,5-dicarbonitriles as agonists for ARs [45, 87],
IJzerman et al. reported a series of five 2-amino-6-(1H-
imidazol-2-ylmethylsulfanyl)-4-(substituted)phenyl pyridine-
3,5-dicarbonitrile derivatives displaying high-potency
agonistic activity for the hA2B AR with somewhat significant
selectivity versus the hA3 AR subtype [88]. The ability of
such compounds to activate the human A2B AR has been
determined through cAMP assay in CHO cells stably
expressing this receptor. For comparison, affinity for the
hA1,h A 2A,a n dh A 3 ARs stably expressed on CHO cells
(A1)o rH E K 2 9 3c e l l s( A 2A,A 3) was determined in radio-
ligand binding studies with [
3H]DPCPX, [
3H]ZM241385
and [
125I]I-ABMECA as radioligands, respectively (Table 5).
All the reported compounds interacted with the hA2B AR,
with EC50 ranging from 9 to 34 nM. Percentages of efficacy
in modulation (inhibition for A1 and A3, stimulation for A2A
and A2B ARs) of the cAMP production functional assay
reported in Table 5 highlighted that both the nature and the
position of the substituent at the 4-phenyl ring considerably
affect the intrinsic efficacy of the examined molecules,
among which A2B AR partial and full agonists have been
identified. 2-Amino-4-(3-hydroxyphenyl)-6-(1H-imidazol-2-
ylmethylsulfanyl)pyridine-3,5-dicarbonitrile (50, LUF5835)
displayed the highest efficacy of the series, 92% compared
with the reference agonist NECA, combined with a low EC50
of 10 nM. The 4-p-methoxy-phenyl derivative 52
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(efficacy of 33% compared with NECA) of the hA2B AR.
The authors proved that the effect on cAMP production was
mediated by interaction of the reported compounds with the
hA2B AR, establishing that the potent AR antagonist
CGS15943 was able to cause a dose-dependent decrease of
the cAMP production induced by NECA and by the
examined structures. The 4-p-OH-phenyl derivative (49,
LUF5834) is of particular interest, thanks to its high potency
at the hA2B AR (EC50=12 nM) associated with a significant
selectivity versus the hA3 AR subtype (Ki=538 nM, efficacy
74%). This ligand can be considered a useful tool for
distinguishing the relative contributions of the A2B and A3
ARs to mast-cell-mediated activation of angiogenesis, a
process that seems to be regulated by a combined action of
A2B and A3 AR subtypes [88]. The 3-methoxyphenyl
derivative 51 and the 4-methoxyphenyl derivative 52 also
showed appreciable selectivity for A2B versus A2A ARs (3-
and 24-fold, respectively) but reduced selectivity for A2B
versus A3 ARs (2.1- and 2.6-fold, respectively) in compar-
ison with the corresponding 3/4-hydroxyphenyl analogues
50 (Ki A2A/EC50 A2B=2.1; Ki A3/EC50 A2B=10.4) and 49
(Ki A2A/EC50 A2B=2.3; Ki A3/EC50 A2B=45).
A recent patent application [89] claimed the possible
employment of 2-amino-6-[({2-[(substituted)phenylamino]-
1,3-thiazol-4-yl}methyl)thio]-4-(substituted)phenyl-pyri-
dine-3,5-dicarbonitrile derivatives of general formula I and
II (compounds 53–56, Fig. 3, Table 6) as dual A1/A2B AR
agonists for treating diseases such as dyslipidemia, meta-
bolic syndrome and diabetes, metabolic syndrome and
diabetes in connection with hypertonia and diseases of the
cardiovascular system. Moreover, new experimental evi-
dence points to compound 53 as the representative dual A1/
A2B AR agonist (EC50 values of 0.2, 0.1 and 236 nM for
A1,A 2B and A2A hAR subtypes, respectively), also
potentially useful for treating and/or preventing hyperten-
sion, hypertonya, restenosis and thrombosis [90].
Compounds 2-[6-amino-3,5-dicyano-4-(4-hydroxyphenyl)
pyridin-2-ylsulfanyl]acetamide (57) and 2-[6-amino-3,5-
dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-ylsul-
fanyl]acetamide (BAY-60–6583, 58)h a v eb e e ne x a m i n e da s
A2B AR agonists for their potential in treating disorders of
the coronary arteries and atherosclerosis [45], as well in the
production of pharmaceuticals for prophylaxis and/or
treatment of ischaemia-reperfusion injury [91]. Other
possible clinical developments seem related to limitation
of reperfusion cellular damage in mammals, especially in
humans, following, for example, myocardial infarction,
coronary artery bypass grafting and open heart surgery. In
particular, compound BAY-60–6583 is under preclinical-
phase investigation for treating angina pectoris. BAY-60–
6583, characterised with CHO cells expressing recombinant
human A1,A 2A or A2B ARs, showed EC50 values for
receptor activation >10,000 nM for both A1 and A2A AR
and 3 nM for A2B AR subtypes. Moreover, it showed no
agonistic activity in the adenosine A3-Gα16 assay up to a
concentration of 10 μM[ 46]. In a rabbit model of
myocardial ischaemic injury, this compound (100 mcg/kg
i.v.) reduced the infarction area when administered to
ischaemic rabbit hearts just prior to reperfusion, thus
mimicking the effects of postconditioning procedure, which
consisted of four cycles of 30-s reperfusion/30-s occlusion
following ischaemia. Furthermore, the addition of nonspe-
cific and A2B AR-selective antagonists (MRS 1754 [71])
blocked protection from postconditioning. Together, these
data demonstrate that protection from postconditioning
involves A2B ARs [92].
The possible use of substituted 2-thio-3,5-dicyano-4-
phenyl-6-aminopyridines (with particular attention to com-
pound 59) for the production of a medicament for the
prophylaxis and/or treatment of nausea and vomiting is
under investigation [93].
Conclusions
With this review, we provide an overview of the latest
advancements in the research field concerning the identifi-
cation of agonists for A2B AR, with particular attention to
the past 2 years. The lack of agonists endowed with
satisfactory levels of A2B AR potency and selectivity has
hampered the pharmacological characterisation of this
potential therapeutic target. Important progresses in the
field has been newly attained, thanks to the identification of
both nucleoside-like (1-deoxy-1-{6-[N′-(furan-2-carbonyl)-
hydrazino]-9H-purin-9-yl}-N-ethyl-β-D-ribofuranurona-
mide, 19) and nonadenosine (BAY-60–6583) molecules
with undoubtedly improved in vitro pharmacological
profile. A schematic overview of the most effective
substitutions of adenosine and nonadenosine derivatives is
furnished in Fig. 4. In particular, the gain in A2B AR
selectivity promoted in these new agonists would provide
useful pharmacological probes for exploring the role of in
vivo receptor activation, and thus a more complete insight
of the prospective employment of A2B AR ligands in
clinical therapy might be offered.
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